GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Brenipatide

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
10 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

10 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Brenipatide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07219173

    A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

    Not yet reported Eli Lilly and Company 531 participants Est. completion 2028-06 121 sites Stand-alone
    Other conditions: Asthma
    View official trial listing →
  • Recruiting NCT NCT07219953

    A Study of Brenipatide in Participants With Alcohol Use Disorder

    Not yet reported Eli Lilly and Company 1100 participants Est. completion 2028-04 116 sites
    Alcohol use disorder
    View official trial listing →
  • Recruiting NCT NCT07219966

    A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

    Not yet reported Eli Lilly and Company 1100 participants Est. completion 2028-04 118 sites
    Alcohol use disorder
    View official trial listing →
  • Recruiting NCT NCT07223840

    A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

    Not yet reported Eli Lilly and Company 222 participants Est. completion 2027-02 29 sites Stand-alone
    Other conditions: Smoking
    View official trial listing →
  • Recruiting NCT NCT07286175

    A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    Not yet reported Eli Lilly and Company 400 participants Est. completion 2027-11 87 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Recruiting NCT NCT07410507

    A Study of Brenipatide in Adult Participants With Schizophrenia

    Not yet reported Eli Lilly and Company 450 participants Est. completion 2027-11 103 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Recruiting NCT NCT07412756

    A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    Not yet reported Eli Lilly and Company 1000 participants Est. completion 2028-02 179 sites Stand-alone
    Other conditions: Depressive Disorder, Major
    View official trial listing →
  • Recruiting NCT NCT07420283

    A Study of Brenipatide in Participants With Opioid Use Disorder

    Not yet reported Eli Lilly and Company 465 participants Est. completion 2028-03 59 sites Stand-alone
    Substance use disorder
    View official trial listing →
  • Recruiting NCT NCT07545759

    A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

    Not yet reported Eli Lilly and Company 531 participants Est. completion 2027-11 89 sites
    Other conditions: Irritable Bowel Syndrome, Diarrhea
    View official trial listing →
  • Recruiting NCT NCT07545772

    A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

    Not yet reported Eli Lilly and Company 342 participants Est. completion 2027-09 70 sites
    Other conditions: Irritable Bowel Syndrome, Constipation
    View official trial listing →
  • Active, not recruiting NCT NCT07476118

    A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

    Not yet reported Eli Lilly and Company 150 participants Est. completion 2027-02 3 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07759245

    A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

    Not yet reported Eli Lilly and Company 606 participants Est. completion 2028-11 128 sites Stand-alone
    Other conditions: Pulmonary Disease, Chronic Obstructive
    View official trial listing →
  • Not yet recruiting NCT NCT07775300

    A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    Not yet reported Eli Lilly and Company 1000 participants Est. completion 2029-02 169 sites Stand-alone
    Other conditions: Depressive Disorder, Major
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.